Boston Scientific Corporation
BSX
$51.23
$0.771.52%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.68% | 98.96% | 18.94% | 60.98% | 145.99% |
| Total Depreciation and Amortization | 5.65% | 8.00% | 4.89% | 11.76% | 8.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 273.75% | -295.00% | -21.46% | 231.15% | -120.67% |
| Change in Net Operating Assets | -68.24% | -34.96% | -52.16% | -73.49% | 211.48% |
| Cash from Operations | 14.62% | -35.67% | -6.32% | 34.03% | 58.18% |
| Capital Expenditure | -24.20% | 5.35% | -26.71% | -1.12% | -1.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 80.67% | -118.83% | 97.40% | 77.28% | -2,002.08% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,015.00% | 247.30% | -700.00% | 46.28% | 158.82% |
| Cash from Investing | -73.71% | -18.20% | 86.18% | 64.82% | -315.50% |
| Total Debt Issued | 167,400.00% | -- | -100.00% | -- | -- |
| Total Debt Repaid | 95.86% | 80.24% | -- | -- | -- |
| Issuance of Common Stock | -84.38% | -29.57% | -28.57% | 19.79% | 23.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -30.51% | 36.43% | 600.00% | 95.51% | -2,850.00% |
| Cash from Financing | -20.59% | -211.59% | -185.98% | -1,585.71% | -1,516.67% |
| Foreign Exchange rate Adjustments | -50.00% | -- | 133.33% | -133.33% | 300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -400.00% | -261.02% | 132.83% | 277.97% | -131.45% |